Evidence map›Paper›PMID 30822359›Full record

Trial reportThe British journal of dermatology2019

Oxymatrine therapy inhibited epidermal cell proliferation and apoptosis in severe plaque psoriasis.

H-J Shi, H Zhou, A-L Ma, L Wang, Q Gao, N Zhang, H-B Song, K-P Bo, W Ma

Open access · bronzeAbstract readClinical Trial
In one paragraph

Trial report in The British journal of dermatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed, 2 pooled it
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 2 syntheses or guidelines pooled it, 60 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Review
  7. Dialogue between programmed cell death and psoriasis.Postepy dermatologii i alergologii · 2025
    Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

H-J ShiDepartment of Dermatovenereology, General Hospital of Ningxia Medical University, Yinchuan, 750004, China.ORCID 0000-0002-2998-1637
H ZhouDepartment of Dermatovenereology, Muping Traditional Chinese Medicine Hospital, Yantai, 264100, China.
A-L MaDepartment of Dermatovenereology, General Hospital of Ningxia Medical University, Yinchuan, 750004, China.
L WangDepartment of Dermatovenereology, General Hospital of Ningxia Medical University, Yinchuan, 750004, China.
Q GaoDepartment of Dermatovenereology, General Hospital of Ningxia Medical University, Yinchuan, 750004, China.
N ZhangDepartment of Dermatovenereology, General Hospital of Ningxia Medical University, Yinchuan, 750004, China.
H-B SongDepartment of Dermatovenereology, Ningxia Medical University, Yinchuan, China.
K-P BoDepartment of Dermatovenereology, Ningxia Medical University, Yinchuan, China.
W MaDepartment of Dermatovenereology, Ningxia Medical University, Yinchuan, China.
Ningxia Medical University · CNYantaishan Hospital · CN

Funding

Natural Science Foundation of Ningxia NZ17154
6 · The paper itself

Abstract

backgroundPsoriasis is a chronic skin disorder that manifests as epidermal keratinocyte hyperplasia.

objectivesWe examined the effect of oxymatrine treatment on cell proliferation and apoptosis in skin lesions of psoriasis. PATIENTS AND

methodsPatients with severe plaque psoriasis were treated with oxymatrine or with acitretin. The skin lesions were stained with proliferating cell nuclear antigen (PCNA), Ki-67 and Bcl-2, as well as examined by terminal deoxynucleotidyl transferase-mediated dUTP nick-end labelling (TUNEL). We performed correlations of the Psoriasis Area and Severity Index (PASI) and the proliferation and apoptosis index.

resultsOxymatrine significantly reduced the psoriasis lesions as demonstrated by the reduced PASI score after treatment [6·91; 95% confidence interval (CI) 5·00-8·81, P < 0·001]. In the oxymatrine group, the mitotic index was 26·15 (95% CI 24·80-27·49) before oxymatrine treatment, decreasing to 14·52 (95% CI 13·82-15·25; P < 0·001) after treatment, but remained higher than the normal group (6·24; 95% CI 5·87-6·61, P < 0·001). Oxymatrine also inhibited the proliferation of epidermal cells in the skin lesion as indicated by the reduced proliferation index after treatment (P < 0·01). In addition, oxymatrine treatment reduced cellular apoptosis as shown by increased Bcl-2 expression and a decrease in TUNEL-positive cells. The PASI score was positively correlated with mitotic index, proliferation index and apoptotic index (TUNEL), but negatively correlated with Bcl-2 expression.

conclusionsOxymatrine treatment reduced proliferation but inhibited apoptosis of cells in the skin lesion. The balance between cell proliferation and turnover may contribute to the significant alleviation of psoriasis by oxymatrine. What's already known about this topic? Psoriasis manifests as epidermal keratinocyte hyperplasia with proliferation, keratinocyte maturation and turnover rates. Current drugs for psoriasis may inhibit cell proliferation but could not adjust the balance of cell division, differentiation and apoptosis. What does this study add? We studied the efficacy of oxymatrine in the treatment of psoriasis and analysed the correlation of skin lesions, proliferation and apoptosis index before and after oxymatrine treatment. What is the translational message? Our study has demonstrated that oxymatrine is effective in the treatment of severe plaque psoriasis. It has comparable efficacy with acitretin. Because acitretin treatment was sometimes associated with metabolic abnormalities, our study suggests oxymatrine therapy as an alternative treatment for psoriasis in the context of acitretin allergy or adverse reactions.

Indexed as

AcitretinAdultAlkaloidsApoptosisBiopsyCell ProliferationDrug Administration ScheduleFemaleHumansInfusions, IntravenousKeratinocytesMaleMatrinesPsoriasisQuinolizinesSeverity of Illness IndexAcitretinAlkaloidsMatrinesoxymatrineQuinolizines

Identifiers

PMID30822359
PMCPMC6899633
OpenAlexW2918870428

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.